Powered by OpenAIRE graph
Found an issue? Give us feedback

Plymouth University

Plymouth University

Top 100 values are shown in the filters
Results number
491 Projects, page 1 of 99
  • Funder: European Commission Project Code: 253897
  • Funder: European Commission Project Code: 326933
  • Funder: European Commission Project Code: 660711
    Overall Budget: 195,455 EURFunder Contribution: 195,455 EUR

    The NeuPheMi project presents a novel approach in the neuroscientific study of mental imagery. Mechanisms of mental imagery are not yet well understood and while traditional approaches investigated their neural correlates based mostly on problem-solving tasks, NeuPheMi proposes to shed the light on the neural correlates of experiencing mental imagery. By taking into account the subjective experience and using electroencephalography and brain stimulation techniques to investigate the dynamic of neuronal activity during mental imagery in an original neurophenomenological approach, NeuPheMi is expected to bring a better understanding of the neuronal basis of mental imagery and extend our comprehension of human consciousness. Conjointly investigating the subjective experience and cerebral activity during mental imagery is a considerable research challenge, with tremendous benefits to both applied and basic science – directly in line with the European research priorities, as underlined in the Horizon2020 Future and Emerging Technologies initiative Knowing, doing and being: cognition beyond problem solving.

  • Funder: European Commission Project Code: 618930
    Powered by Usage counts
  • Funder: UK Research and Innovation Project Code: G0500290
    Funder Contribution: 2,053,350 GBP

    We plan to evaluate whether a cannabis-based medicine (delta 9-THC) has an effect on slowing accumulation of disability in progressive multiple sclerosis (MS) over three years. MS is the commonest cause of disability in young adults and the majority of people affected eventually develop a progressive form of the condition, thought to be due to destruction of nerve cells. MS treatments can be divided into those aimed at relieving symptoms and those that may alter the course of the condition. Unfortunately, few medicines are effective in MS, and none have been shown to have any effect in the later stages of progressive disease. The recent Cannabinoids in MS (CAMS) study investigated the effects of cannabis–based medicines on muscle stiffness (spasticity) in MS over a fifteen week period, with an option for participants to continue study medication for up to a year. Although the study did not demonstrate any effects on spasticity after fifteen weeks as measured by independent assessors, there was evidence that patients felt that the cannabis medicines helped many symptoms and the study did provide preliminary evidence to suggest that delta 9-THC may reduce accumulation of disability in the longer-term. In addition, new scientific evidence has emerged to suggest that some constituents of cannabis may help nerve cells to survive (neuroprotection). It is therefore possible that this medication may not only help treat symptoms of MS, but may also alter the course of the condition and be neuroprotective. The CAMS study also highlighted the limitations of measuring the effects of treatments in chronic disease, especially the differences between patient experience and independent assessment e.g. by a doctor. In our new study we will use both old and new ways of assessing the effects of cannabis-based medicines and will continue to develop measurement methods from the patient perspective. This should lead to more effective ways of assessing new treatments in the future.


Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.